

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

RECEIVED
SECRETARY OF THE SENATE

02 AUG 22 PM 3:33

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Watson Pharmaceuticals, Inc. (New Jersey)			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 1101 17th Street N.W. Suite 500 City Washington State/Zip (or Country) DC 20036			
3. Principal Place of Business (if different from line 2) City Corona State/Zip (or Country) CA 92880			
4. Contact Name G. Thomas Long	Telephone 202-452-1102	E-mail (optional) gtlong@earthlink.net	5. Senate ID # 63837-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID # 35518000

TYPE OF REPORT 8. Year 2002 Midyear (January 1-June 30) ☒ OR Year End (July 1-Dec)

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ >> Termination Date 11/1/2002 No Lobby

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input type="checkbox"/> >> \$ <u>Income (nearest \$20,000)</u>	\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$200,000.00</u> Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of:
	<input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definition
	<input type="checkbox"/> Method B. Reporting amounts under section 6033 the Internal Revenue Code
	<input type="checkbox"/> Method C. Reporting amounts under section 162(c) Internal Revenue Code

Signature _____

Date 8/14/2002

Registrant Name: Watson Pharmaceuticals, Inc. (New Jersey)

Client Name: Watson Pharmaceuticals, Inc. (New Jersey)

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues

HR 5263 S 2801, FY 2003 Agriculture Appropriations Bill, FDA Appropriations: OGD

17. House(s) of Congress and Federal agencies contacted

House of Representatives
Senate

☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Long, G. Thomas	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____

Date 8/14/2002

Printed Name and Title

G. Thomas Long - Vice President, Government Affairs
Filing #b56c127b-57cc-49d2-a6e4-fa1f389f956f - Page 3 of 14

Registrant Name: Watson Pharmaceuticals, Inc. (New Jersey)Client Name: Watson Pharmaceuticals, Inc. (New Jersey)

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues

**HR 1862, Greater Access to Affordable Pharmaceuticals Act,
S 2677, Consumer Access to Prescription Drugs Improvement Act of 2002,
S 812, Greater Access for Affordable Pharmaceuticals Act,**

17. House(s) of Congress and Federal agencies contacted
House of Representatives
Senate

☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Long, G. Thomas	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____

Date 8/14/2002

Registrant Name: Watson Pharmaceuticals, Inc. (New Jersey)Client Name: Watson Pharmaceuticals, Inc. (New Jersey)

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

**HR 3448, Public Health Security and Bioterrorism Response Act of 2001,
Letters and visits to Members of Congress and Federal officials regarding Food and Drug Administration re
activity covering issues and products of interest to the Registrant.**

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

**Department of Health & Human Services
Food & Drug Administration
House of Representatives
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Long, G. Thomas	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____

Date 8/14/2002

Registrant Name: Watson Pharmaceuticals, Inc. (New Jersey)

Client Name: Watson Pharmaceuticals, Inc. (New Jersey)

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code LBR (one per page)

16. Specific Lobbying issues
S 754, Drug Competition Act of 2001,

17. House(s) of Congress and Federal agencies contacted
House of Representatives
Senate

☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Long, G. Thomas	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date 8/14/2002

Registrant Name: Watson Pharmaceuticals, Inc. (New Jersey)Client Name: Watson Pharmaceuticals, Inc. (New Jersey)

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

**HR 4954, Medicare Modernization & Prescription Drug Act of 2002,
S 2625, Medicare Outpatient Prescription Drug Act of 2002,**

17. House(s) of Congress and Federal agencies contacted

**House of Representatives
Senate**

☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Long, G. Thomas	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if NoneSignature _____ Date 8/14/2002

Registrant Name: Watson Pharmaceuticals, Inc. (New Jersey)Client Name: Watson Pharmaceuticals, Inc. (New Jersey)

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific Lobbying issues

Clarify that generic drug development activities may qualify for Research & Development tax credits.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

Department of Treasury
House of Representatives
Internal Revenue Service
Senate


18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Long, G. Thomas	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature


Date 8/14/2002

